BioNxt Solutions Inc. (BNXTF)
OTCMKTS
· Delayed Price · Currency is USD
0.3400
+0.0150 (4.62%)
Apr 24, 2025, 9:30 AM EDT
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 17.10K CAD in the quarter ending September 30, 2024, with 198.55% growth. This brings the company's revenue in the last twelve months to 42.01K, down -89.20% year-over-year. In the year 2023, BioNxt Solutions had annual revenue of 372.25K with 25.15% growth.
Revenue (ttm)
42.01K CAD
Revenue Growth
-89.20%
P/S Ratio
1,230.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
38.27M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
BioNxt Solutions News
- 5 weeks ago - BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement - Accesswire
- 7 weeks ago - BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement - Accesswire
- 2 months ago - BioNxt Solutions Announces Debenture Unit Financing - Accesswire
- 2 months ago - Clarification of Promotional Activities - Accesswire
- 2 months ago - BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion - Accesswire
- 3 months ago - BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities - Accesswire
- 3 months ago - BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities - Accesswire
- 4 months ago - BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP - Accesswire